Biointron is excited to announce our participation in the 13th Antibody Industrial Symposium (AIS2025), taking place on June 25-26, 2025, at the Palais des Congrès de Tours in Tours, France.

This week, computationally designed antibody therapeutics have been high on the news, leveraging advanced deep learning and AI-driven methodologies to accelerate the discovery and optimization of antibodies.

This year’s Nobel prize in chemistry was awarded last month for using computationally designing novel proteins and predicting structures! The first half of the prize was awarded to John Jumper and Demis Hassabis, who developed AlphaFold, an artificial intelligence (AI) program that can predict a protein’s shape and function from its chemical sequence.

Immunoinformatics, also known as computational immunology, is the combination of computer science and experimental immunology. Due to technological advancements in immunology research, large quantities of data are now available from genome sequencing, scientific literature, and clinical records.

The technological advancements of the past few decades have revolutionized antibody discovery, production, and optimization. A particularly exciting approach is computational protein modeling and design, which have benefitted from the massive volume of next generation sequencing data and a combination of bioinformatics, machine learning, and artificial intelligence (AI).

VHHs, also known as single-domain antibodies (sdAbs) or nanobodies, are the smallest antigen-binding fragments derived from heavy-chain-only antibodies found in camelids, such as alpacas, llamas and camels.

BIO Asia 2024 was held in Taiwan on 24-28 July, 2024. The event brought together bioindustry leaders from North America, Europe and Asia to explore business opportunities and to engage with Taiwan's emerging biotech sector. This year’s theme, Global View, Asian Touch, showcased the opportunities that exist within Asian’s fast-moving economies, its dynamic and innovation-generating biomedical ecosystems, and its globally-connected bioindustry production and value chains.

Antibody Engineering & Therapeutics Europe 2024 was held in London, UK on 4-6 June, 2024. As Europe's leading antibody conference for accelerating next-generation antibodies to commercial success, topics discussed included:Emerging modalities: ADCs, degraders, and beyondFc

The BIO International Convention 2024 was held in San Diego, CA from June 3-6. It is the largest event for biotechnology with over 18,500 industry leaders in attendance, sharing the latest advancements in the industry. The most popular topics included:AI and Digital HealthNext Generation

MAGMA-seq is an integrated technology for antibody wide mutational scanning. DOI:10.1038/s41467-024-48072-zThe use of bioinformatics and computational methods were of high interest in several papers published this past week. Protein language models, akin to natural language processing tools, p

Here at the AACR Annual Meeting 2024, there are over 7000 abstracts, 300 poster presentations, and 50 symposia all about cancer research. A few topics that are currently trending in the conference include cancer vaccines, AI for diagnostics, novel immunotherapies, and antibody-drug conjugates (ADCs) as a new modality.

Explore antibody discovery technologies like phage display, yeast display, & computational tools. Learn about trends in multi-specific antibodies & AI integration.

Explore how deep learning models like DeepH3 & DeepAb predict antibody structures, aiding in the design of high-affinity antibodies by modeling CDR loops & FV regions.

Learn how in silico tools like SCM & TAP assess antibody developability, predicting properties like viscosity, immunogenicity & stability for therapeutic success.

Explore how sequence, structural, therapeutic, and experimental databases revolutionize antibody engineering, enhancing discovery, design, and therapeutic development.